Crizotinib

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Recurrent Childhood Anaplastic Large Cell Lymphoma

Conditions

Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma

Trial Timeline

Sep 21, 2009 → Dec 31, 2018

NCT ID

NCT00939770

About Crizotinib

Crizotinib is a phase 1/2 stage product being developed by Pfizer for Recurrent Childhood Anaplastic Large Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00939770. Target conditions include Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma.

What happened to similar drugs?

6 of 20 similar drugs in Recurrent Childhood Anaplastic Large Cell Lymphoma were approved

Approved (6) Terminated (0) Active (14)

✅Zopapogene imadenovec (Zopa)PrecigenApproved

✅Bevacizumab + Capecitabine + Everolimus + ExemestaneNovartisApproved

✅FamciclovirNovartisApproved

✅Pidotimod + PlaceboAlmirallApproved

✅BaclofenBrain BiotechApproved

🔄Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03085186	Pre-clinical	Completed	—	—	Inflammatory Myofibroblastic Tumour
NCT02473497	Pre-clinical	Completed	—	—	Neoplasm
NCT02824094	Pre-clinical	Completed	—	—	Neoplasms
NCT05160922	Approved	Active	Dec 27, 2021	Mar 21, 2028	NSCLC
NCT04084717	Phase 2	Recruiting	Dec 3, 2019	Jun 1, 2025	Non-squamous Non-small-cell Lung Cancer
NCT03672643	Approved	Terminated	Jan 28, 2019	Sep 28, 2023	ALK or ROS1-positive NSCLC
NCT03088930	Phase 2	Completed	Dec 13, 2017	Jan 13, 2021	Lung Cancer, Nonsmall Cell
NCT03375242	Pre-clinical	Recruiting	Oct 25, 2017	Mar 26, 2027	Non-small Cell Lung Cancer
NCT02612194	Phase 2	Terminated	Sep 27, 2016	Nov 21, 2019	Urinary Bladder Neoplasms
NCT02679170	Pre-clinical	Completed	Jun 29, 2016	May 4, 2022	Non-Small Cell Lung Cancer
NCT02223819	Phase 2	Completed	Mar 1, 2015	Jul 3, 2019	Uveal Melanoma
NCT02270034	Phase 1	Completed	Aug 13, 2014	Oct 26, 2020	Glioblastoma Multiforme (Grade IV) of Cerebellum
NCT01500824	Phase 2	Withdrawn	May 1, 2014	May 1, 2016	Non-Small Cell Lung Cancer
NCT02183870	Phase 2	Completed	May 1, 2014	Feb 29, 2020	Lung Cancer
NCT01945021	Phase 2	Completed	Sep 30, 2013	Jan 22, 2020	Non Small Cell Lung Cancer
NCT02034981	Phase 2	Completed	Aug 1, 2013	Dec 6, 2023	Hematologic Cancers
NCT01121588	Phase 1	Terminated	Mar 22, 2011	Sep 7, 2023	Neoplasms Malignant
NCT01297595	Phase 1	Completed	Mar 1, 2011	Apr 1, 2011	Healthy
NCT01154218	Phase 1	Completed	Aug 1, 2010	Nov 1, 2010	Healthy
NCT01125904	Phase 1	Completed	Jun 1, 2010	Jun 1, 2010	Healthy

Competing Products

20 competing products in Recurrent Childhood Anaplastic Large Cell Lymphoma

See all competitors

Product	Company	Stage	Hype Score
Doxorubicin Hydrochloride Liposome Injection	Dr. Reddy's Laboratories	Phase 1	26
KPL-914	Kiniksa Pharmaceuticals	Phase 2	29
KPL-387	Kiniksa Pharmaceuticals	Phase 2	36
Rilonacept + Placebo	Kiniksa Pharmaceuticals	Phase 3	34
Enzastaurin (LY317615) + Carboplatin	Eli Lilly	Phase 1	29
Zopapogene imadenovec (Zopa)	Precigen	Approved	44
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2	Precigen	Phase 1/2	30
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab	Perspective Therapeutics	Phase 1/2	33
Ramucirumab + Pembrolizumab	Eli Lilly	Phase 2	39
Gemcitabine and UFTE chemotherapy	Yuhan	Phase 2	35
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + Pembrolizumab	Daiichi Sankyo	Phase 1/2	39
Ifinatamab deruxtecan	Daiichi Sankyo	Phase 2	42
Trastuzumab Deruxtecan	Daiichi Sankyo	Phase 1	36
PLX3397	Daiichi Sankyo	Phase 2	27
erlotinib + etoposide	Astellas Pharma	Phase 2	27
Drug Combination Therapy	Sun Pharmaceutical	Phase 2	42
Niraparib + Anlotinib	Sun Pharmaceutical	Phase 2	35
Eribulin Mesylate	Eisai	Pre-clinical	26
Lenvatinib + Everolimus	Eisai	Phase 1/2	32
E7090	Eisai	Phase 2	42